| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
VERA
Vera Therapeutics
|
Jul 09, 2026 | BUY |
Strong Buy
+69.4% avg upside
19 analysts
|
$91.00
116.66% Upside
|
+0.0% |
|
CMPS
COMPASS Pathways
|
Jul 08, 2026 | BUY |
Strong Buy
+62.4% avg upside
19 analysts
|
$21.00
53.87% Upside
|
-0.9% |
|
CRNX
Crinetics Pharmaceuticals
|
Jul 08, 2026 | HOLD |
Buy
-9.7% avg upside
21 analysts
|
$85.00
1.60% Upside
|
+0.0% |
|
RLYB
Rallybio
|
Jul 06, 2026 | HOLD |
Buy
+49.4% avg upside
8 analysts
|
— | +0.1% |
|
JSPR
Jasper Therapeutics
|
Jul 06, 2026 | HOLD |
Buy
+5271.0% avg upside
17 analysts
|
— | +3.4% |
|
DYN
Dyne Therapeutics
|
Jun 04, 2026 | BUY |
Strong Buy
+62.9% avg upside
30 analysts
|
$33.00
40.99% Upside
|
+32.0% |
|
AVLN
Avalyn Pharma Inc
|
May 26, 2026 | BUY |
Strong Buy
+85.3% avg upside
3 analysts
|
$51.00
81.77% Upside
|
· |
|
ABBV
AbbVie
|
May 15, 2026 | BUY |
Strong Buy
-6.7% avg upside
46 analysts
|
$235.00
5.17% Downside
|
+17.9% |
|
ARGX
Argenx Se
|
May 15, 2026 | BUY |
Strong Buy
-14.4% avg upside
46 analysts
|
$1059.00
20.64% Upside
|
+9.8% |
|
ASND
Ascendis Pharma
|
May 15, 2026 | BUY |
Strong Buy
+0.8% avg upside
24 analysts
|
$329.00
21.66% Upside
|
+12.4% |
|
VRDN
Viridian Therapeutics
|
May 15, 2026 | BUY |
Strong Buy
+78.3% avg upside
32 analysts
|
$26.00
31.75% Upside
|
+17.4% |
|
SRPT
Sarepta Therapeutics
|
May 15, 2026 | HOLD |
Buy
+215.0% avg upside
49 analysts
|
$19.00
0.30% Upside
|
+8.0% |
|
RARE
Ultragenyx Pharmaceutical
|
May 11, 2026 | BUY |
Strong Buy
+96.9% avg upside
36 analysts
|
$33.00
2.47% Downside
|
+28.6% |
|
DNTH
Dianthus Therapeutics
|
May 11, 2026 | BUY |
Strong Buy
-8.0% avg upside
29 analysts
|
$120.00
23.05% Upside
|
+12.0% |
|
MIRM
Mirum Pharmaceuticals
|
May 07, 2026 | BUY |
Strong Buy
-4.0% avg upside
21 analysts
|
$138.00
12.99% Upside
|
+25.0% |
|
KRYS
Krystal Biotech
|
May 05, 2026 | BUY |
Strong Buy
-31.7% avg upside
19 analysts
|
$300.00
17.94% Downside
|
+28.5% |
|
TVTX
Travere Therapeutics
|
May 05, 2026 | BUY |
Strong Buy
-16.8% avg upside
22 analysts
|
$52.00
8.12% Downside
|
+29.1% |
|
FBRX
Forte Biosciences
|
May 04, 2026 | BUY |
Strong Buy
-7.3% avg upside
14 analysts
|
$65.00
48.04% Upside
|
-18.9% |
|
MGTX
Meiragtx Holdings
|
Apr 01, 2026 | BUY |
Strong Buy
+94.2% avg upside
13 analysts
|
$18.00
34.46% Upside
|
+55.6% |
|
DMRA
Damora Therapeutics
|
Mar 25, 2026 | BUY |
Strong Buy
-4.4% avg upside
19 analysts
|
$46.00
61.28% Upside
|
· |
|
DFTX
Definium Therapeutics
|
Mar 02, 2026 | BUY |
Strong Buy
-8.4% avg upside
20 analysts
|
$26.00
44.67% Downside
|
+182.0% |
|
INSM
Insmed
|
Feb 26, 2026 | BUY |
Strong Buy
+50.3% avg upside
36 analysts
|
$208.00
80.01% Upside
|
-22.9% |
|
BCRX
BioCryst
|
Feb 18, 2026 | BUY |
Strong Buy
+77.0% avg upside
24 analysts
|
$17.00
62.66% Upside
|
+40.1% |
|
EVMN
Evommune, Inc.
|
Feb 10, 2026 | BUY |
Strong Buy
+217.1% avg upside
12 analysts
|
$55.00
316.33% Upside
|
-54.5% |
|
PRQR
ProQR
|
Dec 17, 2025 | BUY |
Strong Buy
+552.9% avg upside
18 analysts
|
$5.00
189.08% Upside
|
-32.0% |
|
CABA
Cabaletta Bio
|
Dec 17, 2025 | HOLD |
Strong Buy
+367.8% avg upside
16 analysts
|
$4.00
34.39% Upside
|
+42.1% |
|
SPRO
Spero Therapeutics
|
Dec 17, 2025 | HOLD |
Buy
+553.0% avg upside
12 analysts
|
$4.00
90.52% Upside
|
-9.1% |
|
RCKT
Rocket Pharmaceuticals
|
Dec 17, 2025 | HOLD |
Buy
+320.7% avg upside
29 analysts
|
$5.00
27.80% Upside
|
-9.5% |
|
FHTX
Foghorn Therapeutics
|
Dec 20, 2024 | BUY |
Strong Buy
+100.5% avg upside
17 analysts
|
$18.00
202.43% Upside
|
+1.9% |
|
CCCC
C4 Therapeutics
|
May 30, 2023 | BUY |
Strong Buy
+339.8% avg upside
19 analysts
|
$10.00
146.31% Upside
|
+48.7% |
|
INCY
Incyte
|
Aug 03, 2022 | HOLD |
Buy
-14.2% avg upside
47 analysts
|
$78.00
33.13% Downside
|
-10.4% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.